Overview
On 23 March 2009, orphan designation (EU/3/09/622) was granted by the European Commission to Ambit Europe Limited, United Kingdom, for N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-(morpholin-4-yl)ethoxy) imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea di-hydrochloride salt for the treatment of acute myeloid leukaemia.
The sponsorship was transferred to Daiichi Sankyo Development Ltd, United Kingdom, in June 2016.
Key facts
Active substance |
N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-(morpholin-4-yl)ethoxy) imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea di-hydrochloride salt
|
Intended use |
Treatment of acute myeloid leukaemia
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/09/622
|
Date of designation |
23/03/2009
|
Sponsor |
Daiichi Sankyo Development Ltd
Chiltern Place Chalfont Park Gerrards Cross Buckinghamshire SL9 0BG United Kingdom Tel. +44 (0)1753 482 813 Fax +44 (0)1753 899 107 E-mail: info@dsd-eu.com |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: